Cormorant Asset Management’s MacroGenics MGNX Stock Holding History

Cormorant Asset Management’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-707,978	Closed	-$21.2M	–	85
2016 Q3	$21.2M	Hold	707,978	–	–	2.34%	15
2016 Q2	$19.1M	Buy	707,978 +7,978	+1%	+$180K	2.71%	10
2016 Q1	$13.1M	Buy	700,000 +200,000	+40%	+$3.81M	1.98%	15
2015 Q4	$15.5M	Buy	+500,000	New	+$15.2M	1.85%	18

Other funds holding MGNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cormorant Asset Management's MGNX Position: Q4 2016 in Review

Cormorant Asset Management sold out of MacroGenics (MGNX) in Q4 2016, closing a stake of 707,978 shares — an estimated $21.2M sold.

Cormorant Asset Management first reported a position in MGNX in Q4 2015 and held it in 4 quarters. The position peaked at $21.2M in Q3 2016. 131 funds tracked by Wall St. Rank hold MGNX as of Q4 2016.

Cormorant Asset Management reported no remaining MacroGenics position as of Q4 2016 after selling out during the quarter.
Cormorant Asset Management sold 707,978 MacroGenics shares in Q4 2016, an estimated $21.2M.
Cormorant Asset Management first reported a position in MacroGenics in Q4 2015 and held it in 4 quarters.
Cormorant Asset Management's MacroGenics position peaked at $21.2M in Q3 2016.
131 funds tracked by Wall St. Rank held MacroGenics as of Q4 2016.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.